Base of tongue squamous cell carcinomas, outcome depending on treatment strategy and p16 status. A population-based study from the Swedish Head and Neck Cancer Register.
Anders HögmoErik Carl Viktor HolmbergHedda Haugen CangeJohan ReizensteinJohan WennerbergMartin BeranKarin SöderkvistEva HammerlidHelena SjödinLovisa FarneboKarl SandströmLalle Hammarstedt-NordenvallKatarina ZborayovaEva BrunPublished in: Acta oncologica (Stockholm, Sweden) (2022)
In the present retrospective population-based study of BOTSCC brachytherapy was found to be of no beneficial value in curatively intended treatment. An increase in survival was found for EBRT + CT compared to EBRT alone in patients with advanced cases, stages II and III (UICC 8), but none of the regimes was significantly superior to EBRT as a single treatment modality for stage I (UICC 8), provided there was p16 positivity in the tumor. In the small group of patients with p16- tumors, a poorer prognosis was found, but the small sample size did not allow any comparisons between different treatment strategies.